Fujifilm: Latest $1.6bn spend to help quadruple CDMO’s mammalian capacity
Another $1bn+ investment boost, this time at sites in Denmark and Texas, will push Fujifilm Diosynth Biotechnologies into the top tier of CDMOs based on cell culture capacity. The $1.6 billion will be used to expand cell culture manufacturing capabilities at contract development and manufacturing ...
Lotte Group has named MilliporeSigma as its preferred bioprocess vendor to support its burgeoning US-based CDMO business.
In May, Lotte Corpor ...- Charles River opens a plasmid DNA plant in the UK, Batavia Biosciences is building a commercial vaccine facility in the Netherlands, and OrganaBi ...
- Astellas will codevelop immunostimulatory antibody-drug conjugates (iADCs) for three biological targets through a partnership with Sutro Biopharm ...
- The investment will expand drug substance production capabilities at facilities in Blanchardstown and Athlone run by AstraZeneca subsidiary Alexi ...
Recent Tweets
-
RT @Dan5tanton: Two co-founders of Taiwanese firm JHL Biotech were sentenced last month for plotting to steal trade secrets from Ge… https://t.co/0iclK4yS7h
3 months ago
-
RT @frankvinluan: Shutdown comes 8 months after FDA sent a warning letter about a #microbiome metabolic therapy the #biotech was test… https://t.co/FgtTS54Yj0
3 months ago
-
RT @Dan5tanton: A win for CDMO Catalent as it further strengthens its global network, but potentially a loss to the UK taxpayer, wh… https://t.co/Ex9CNdbcf0
3 months ago
-
RT @Dan5tanton: The US Department of Health and Human Services #HHS has terminated a long-term #CDMO partnership with Emergent BioS… https://t.co/bAbKWb3uqQ
8 months ago
